Response to: 'Will SPAR be useful in the usual patients with scleroderma?' by Chattopadhyay et al

Ann Rheum Dis. 2019 Nov;78(11):e126. doi: 10.1136/annrheumdis-2018-214270. Epub 2018 Nov 10.

Authors

Wanlong Wu^{1

2}, Suzana Jordan¹, Oliver Distler³

Affiliations

¹ Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
² Department of Rheumatology, South Campus, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
³ Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland [email protected].

PMID: 30415200
DOI: 10.1136/annrheumdis-2018-214270

No abstract available

Keywords: arthritis; disease activity; pulmonary fibrosis; systemic sclerosis; treatment.

Publication types

Letter
Comment

MeSH terms

Disease Progression
Humans
Lung Diseases, Interstitial*
Scleroderma, Localized*
Scleroderma, Systemic*